Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial

Malaria Journal

Research

Valérie Lameyre¹  Ibrahima Ndiaye²  Jean-Louis A Ndiaye²  Roger Tine²  Babacar Faye²  Corinne Tchania²  Daouda Ndiaye²  Ali Gueye²  Oumar Gaye²  Badara Cissé³  Aichatou Barry⁴ 

[1] Access to Medicines Department, Sanofi Aventis Group, Paris, France;Department of Medical Parasitology, Medical Faculty, Université Cheikh Anta Diop, Dakar, Senegal;Department of Medical Parasitology, Medical Faculty, Université Cheikh Anta Diop, Dakar, Senegal;London School of Hygiene and Tropical Medicine, UK;District of Ndoffane, Ministry of Health, Senegal;

关键词: Malaria;    Falciparum Malaria;    Artesunate;    National Malaria Control Programme;    Malaria Episode;   

DOI  :  10.1186/1475-2875-10-237

 received in 2011-05-13, accepted in 2011-08-12,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundThe use of artemisinin-based combination therapy (ACT) is currently recommended for treating uncomplicated malaria. The objective was to assess the efficacy and safety of repeated administrations of two fixed-dose presentations of ACT - artesunate plus amodiaquine (ASAQ) and artemether-lumefantrine (AL) - in subsequent episodes of Plasmodium falciparum malaria.MethodsA randomized comparative study was conducted in a rural community of central Senegal from August 2007 to January 2009. Children and adults with uncomplicated P. falciparum malaria were randomized to receive open-label ASAQ once daily or AL twice daily for three days. Drug doses were given according to body weight. Treatments for first episodes were supervised. For subsequent episodes, only the first intake of study drug was supervised. ECGs and audiograms were performed in patients ≥12 years of age. Primary outcome was adequate clinical and parasitological response rate (ACPR) after polymerase chain reaction (PCR) correction on day 28 for the first episode.ResultsA total of 366 patients were enrolled in the two groups (ASAQ 184, AL 182) and followed up during two malaria transmission seasons. In the intent-to-treat population, PCR-corrected ACPRs at day 28 for the first episode were 98.4% and 96.2%, respectively, in the ASAQ and AL groups. For the per-protocol population (ASAQ 183, AL 182), PCR-corrected ACPRs at day 28 for the first episode were 98.9% and 96.7%, respectively. A 100% ACPR rate was obtained at day 28 in the 60 and four patients, respectively, who experienced second and third episodes. Treatment-related adverse events were reported in 11.7% of the patients, without significant differences between the two groups. A better improvement of haemoglobin at day 28 was noted in the ASAQ versus the AL group (12.2 versus 11.8 g/dL; p = 0.03). No sign of ototoxicity was demonstrated. A prolongation of the QTc interval was observed in both groups during treatment with no clinical consequence.ConclusionsStudy results confirmed the satisfactory efficacy and safety profile of ASAQ and AL. Moreover, in patients who were treated at least twice, repeated administration of ASAQ or AL did not identify any major safety issues.Trial registrationClinicalTrials.gov identifier NCT00540410.

【 授权许可】

CC BY   
© Ndiaye et al; licensee BioMed Central Ltd. 2011